ArticleMicrobiology spectrum2024
Emergence of plasmid-borne
Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Evolution, Mechanisms, and Therapeutic Implications of Mobile Tetracycline Destructases.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Real-World Therapy with Eravacycline for Complex Infections Caused by Carbapenem-Resistant Pathogens with a Focus on Patients with Severe Burns.Infectious diseases and therapy · 2026Article
- Emergence ofAntimicrobial agents and chemotherapy · 2026Article
- The flexible cotransfer of plasmids drives the dissemination of tet(X4) in swine Escherichia coli.Veterinary research · 2026Article
- Emergence of a KL239-OCL6-ST63 Carbapenem-Resistant Acinetobacter pittii Strain, Co-carrying blaCurrent microbiology · 2026Article
- Phylogenetic diversification and fitness trade-offs of TetA variants in mediating eravacycline resistance inAntimicrobial agents and chemotherapy · 2026Article
- A conjugated polymer antimicrobial agent triggers metabolic cascade-mediated killing of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Dissemination of aFrontiers in microbiology · 2026Article
- Comprehensive genomic analysis of clinical Serratia marcescens isolates unveils extensive dissemination and genetic context of co-occurring of blaBMC genomics · 2025Article
- Tetracyclines in the Modern Era: Global Consumption, Antimicrobial Resistance, Environmental Occurrence, and Degradation Techniques.Antibiotics (Basel, Switzerland) · 2025Review
- Coexistence of blaScientific reports · 2025Article
- Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Frontiers in microbiology · 2025Review
- Genomic epidemiology and anti-biofilm mechanisms of Lactobacillus in ST11 carbapenem-resistantFrontiers in microbiology · 2025Article
- Emergence of NDM-1 on IncR-IncFIA (HI1) plasmid in carbapenem-resistantFrontiers in microbiology · 2025Article
- Emergence of tigecycline-resistantFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omadacycline and eravacycline are gradually being used as new tetracycline antibiotics for the clinical treatment of Gram-negative pathogens. Affected by various tetracycline-inactivating enzymes, there have been reports of resistance to eravacycline and omadacycline in recent years. We isolated a strain carrying the mobile tigecycline resistance gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.